Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Goknur Ozaydin-Yavuz, Ibrahim Halil Yavuz, Hüseyin Serhat İnalöz & Cagdas Boyvadoglu. (2022) Omalizumab is not just an anti-immunoglobulin E. Journal of Dermatological Treatment 33:6, pages 2858-2861.
Read now
Read now
Arzu Didem Yalcin & Ata Nevzat Yalcin. (2021) Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacology and Immunotoxicology 43:1, pages 1-7.
Read now
Read now
Arzu Didem Yalcin & Ata Nevzat Yalcin. (2020) A case of asthma with Behcet’s disease: successful treatment with omalizumab and its effects on recurrent aphthous lesions. Immunopharmacology and Immunotoxicology 42:4, pages 379-382.
Read now
Read now
Ersoy Acer, Hilal Kaya Erdogan, Nihan Yüksel Çanakçı & Zeynep Nurhan Saracoglu. (2019) The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutaneous and Ocular Toxicology 38:1, pages 5-8.
Read now
Read now
Arzu Didem Yalcin, Betul Celik & Ata Nevzat Yalcin. (2016) Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacology and Immunotoxicology 38:3, pages 253-256.
Read now
Read now
Arzu Didem Yalcin. (2016) A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacology and Immunotoxicology 38:2, pages 162-166.
Read now
Read now
Riccardo Asero, Elena Pinter, Alessandro Maria Marra, Alberto Tedeschi, Massimo Cugno & Angelo Valerio Marzano. (2015) Current challenges and controversies in the management of chronic spontaneous urticaria. Expert Review of Clinical Immunology 11:10, pages 1073-1082.
Read now
Read now
Articles from other publishers (16)
Nadja Højgaard Pedersen, Jennifer Astrup Sørensen, Misbah Noshela Ghazanfar, Ditte Georgina Zhang, Christian Vestergaard & Simon Francis Thomsen. (2023) Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. International Journal of Molecular Sciences 24:14, pages 11328.
Crossref
Crossref
Roberta Fachini Jardim Criado & Paulo Ricardo Criado. 2023. Dermatology in Public Health Environments. Dermatology in Public Health Environments
1673
1707
.
Sijia Wang, Mei Lu, Zijun Zhao, Xueting Peng, Liang Li, Chuantao Cheng, Min Fang, Yumin Xia & Yale Liu. (2021) Plasma levels of D-dimer and fibrin degradation products correlate with bullous pemphigoid severity: a cross-sectional study. Scientific Reports 11:1.
Crossref
Crossref
Youin Bae, Sung Hun Kang, Ju Ok Park, Gyeong-Hun Park & Jeong-Hee Choi. (2020) Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergology International 69:2, pages 304-306.
Crossref
Crossref
Matthew C. TattersallAlison S. DasiewiczRobyn L. McClellandAdam D. GepnerMatthew M. KalscheurMichael E. FieldSusan R. HeckbertMohamed H. HamdanJames H. Stein. (2020) Persistent Asthma Is Associated With Increased Risk for Incident Atrial Fibrillation in the MESA. Circulation: Arrhythmia and Electrophysiology 13:2.
Crossref
Crossref
Crhistian-Mario Oblitas, Francisco Galeano-Valle, Laura Vela-De La Cruz, Jorge Del Toro-Cervera & Pablo Demelo-Rodríguez. (2019) Omalizumab as a Provoking Factor for Venous Thromboembolism. Drug Target Insights 13, pages 117739281986198.
Crossref
Crossref
R. Asero. (2017)
ACE
inhibitors may interfere with omalizumab in chronic spontaneous urticaria
. Journal of the European Academy of Dermatology and Venereology 31:8.
Crossref
Crossref
R. Asero. (2017) Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab. Clinical and Experimental Dermatology 42:6, pages 667-669.
Crossref
Crossref
P. Kolkhir, F. André, M. K. Church, M. Maurer & M. Metz. (2017) Potential blood biomarkers in chronic spontaneous urticaria. Clinical & Experimental Allergy 47:1, pages 19-36.
Crossref
Crossref
Rusen Uzun, Arzu Didem Yalcin, Betul Celik, Tangul Bulut & Ata Nevzat Yalcin. (2016) Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone. American Journal of Case Reports 17, pages 666-671.
Crossref
Crossref
Tao Lu, Xiaoyang Jiao, Mengya Si, Ping He, Jinbo Zou, Shuping Zhang & Kang Zeng. (2016) The Correlation of Serums CCL11, CCL17, CCL26, and CCL27 and Disease Severity in Patients with Urticaria. Disease Markers 2016, pages 1-11.
Crossref
Crossref
Riccardo Asero, Alberto Tedeschi, Angelo Valerio Marzano & Massimo Cugno. (2015) Coagulation in Chronic Urticaria. Current Treatment Options in Allergy 2:4, pages 287-293.
Crossref
Crossref
Arzu Didem Yalcin. (2015) Advances in Anti-IgE Therapy. BioMed Research International 2015, pages 1-11.
Crossref
Crossref
AD Yalcin. (2014) ANTI-Ige: An Overview. Global Journal of Allergy, pages 003-012.
Crossref
Crossref
Allen P. Kaplan & Todor A. Popov. (2014) Biologic agents and the therapy of chronic spontaneous urticaria. Current Opinion in Allergy & Clinical Immunology 14:4, pages 347-353.
Crossref
Crossref
Arzu Didem Yalcin. (2014) An Overview of the Effects of anti-IgE Therapies. Medical Science Monitor 20, pages 1691-1699.
Crossref
Crossref